Study of the SCD411 Prefilled Syringe for Treating Adults With Wet Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema, or Diabetic Retinopathy

NCT07501052 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular (Wet) Age-Related Macular Degeneration
Retinal Vein Occlusion
Diabetic Macular Edema
Diabetic Retinopathy

Interventions

DRUG: SCD411 0.05mL (2mg)

Sponsor

Sam Chun Dang Pharm. Co. Ltd.